ICMJE DISCLOSURE FORM

Date:	01/03/20	21								
Your Name:_	CATH	Or a C	HETRING.							
Manuscript T	itle:		nt behandling			distrib	nlow	01	akut	
Manuscript n	umber (if kn	own):	(e) dishell	Lynd	am			/		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
唱		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	AS or declaration from tennik vertice - I personally did not receive any processing Support
11	The state of the state of	Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	on advisory board pr the Norde Neone

5	Payment or honoraria for	× None	
,	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	∠ None	
	testimony		
7	Support for attending	None	Travel grents from Chia, Pharmaceunici
	meetings and/or travel		Travel grand from Crital I Horriceconci
8	Patents planned, issued or	_ None	
	pending		
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	DMC, INGLY That Novo Nortisk
			Advisory bound / Chiesi Spa
10	Leadership or fiduciary role	K None	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	None	
11	Stock of Stock options	None	
12	Receipt of equipment,	✓ None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Februar 26, 20		
Your Name: Henrik Vorder		-120
Manuscript Title: Surfactant	behandling as respiratory distress syndrom	Ca
Manuscript number (if known):	abut respiratory distress syndrom.	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	institution)	ere made to you or to your
		Time frame: Since the initial	planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Funding from the European L Phase II SME Instrument Pro The L/S study was part of a p between Department of Pedia Region Zealand, Denmark an (trading as SIME Clinical AI), focused on developing prever diagnostic methods in neonat	ject number 666668. public-private partnership atrics, Holbaek Hospital, ad SIME Diagnostics Ltd a private company ntative, data-driven	Developing of the POC spectrometer. Payments to SIME At Diagnostics. Concerning the L/S method and the POC spectrometer.
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Time frame: past	36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	_X_None		
3	Royalties or licenses	X None		
4	Consulting fees	SIME AI	for a	ments to Verder H as consultant developing of the L/S method and POC spectrometer

5	Payment or honoraria for	X_None			
	lectures, presentations,				
speakers	speakers bureaus,				
	manuscript writing or				
	educational events	200			
6	Payment for expert	None			
	testimony				
7	Support for attending	None			
/	meetings and/or travel	None			
	meetings and/or draver				
		1			
8	Patents planned, issued or	1			
Ü	pending	SIME AI	Verder H hold part of a patent for L/S		
			test on lung maturity		
9	Participation on a Data	None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	None			
	in other board, society,				
	committee or advocacy				
11	group, paid or unpaid Stock or stock options				
11	Stock of Stock options	SIME AI	Verder H has stock options on		
		1	the POC spectrometer		
12	Receipt of equipment,	X None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	None			
	financial interests				
	X				

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.

Date: 26. februar 2021				
Your name: Peter Schousboes				
Manuscript title: Surfaktantbehandling af respiratorisk distress-syndrom				
Manuscript number (if known): UFL-04-21-0322.R2				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Time frame: Since the initial plan	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Funding from the European Union's Horizon 2020 Phase II SME Instrument Project number 666668. The L/S Study was part of a public-private partnership between Department of Pediatrics. Holbaek Hospital, Region Zealand, Demnark and SIME Diagnostics Ltd. (trading as SIME Clinical AI), a private company focused on developing preventative, data-driven diagnostic methods in neonatology.
		Developing of the POC spectrometer. Payments to SIME AI Diagnostics. Concerning the L/S method and the POC spectrometer.

Click TAB in last row to add extra rows

Time frame: past 36 months

2	Grants or contracts from	∠ None	
	any entity (if not indicated in item #1 above).		
	,		
3	Royalties or licenses		
		I	
4	Consulting fees	☐ None	
		SIME AI	Payments to Schousboe P as consultant for
			developing of the L/S method and the POC
			spectrometer
5	Payment or honoraria for	☑ None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None Non	
	testimony	23 140110	
7	Support for attending	None Non	
	meetings and/or travel	2 (10)	
8	Patents planned, issued or	□ None	
	pending	SIME AI	Schousboe P hold part of a patent for L/S test on
	5	SIIVIL AI	lung maturity
			Turig maturity
9	Participation on a Data	□ None	
	Safety Monitoring Board		
	or Advisory Board		
10	Leadership or fiduciary	None Non	
	role in other board,		
	society, committee or		
	advocacy group, paid or		
	unpaid		
	- '		
11	Stock or stock options	☐ None	
	otock of Stock options	SIME AI	Schousboe P has stock options on the POC
		SIIVIL AI	
			spectrometer
12	Receipt of equipment,	None Non	
	materials, drugs, medical		
	writing, gifts or other		
	services		
	331 ¥1000		
		•	
13	Other financial or non-	⊠ None	
13	Other financial or non-	None Non	
13	Other financial or non- financial interests	⊠ None	

Please place an "X" next to the following statement to indicate your agreement:

🛛 I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.